Jeffrey Sosman
Professor Emeritus, Medicine · McGaw Medical Center of Northwestern University
Credentials: · · ·
History
- 1984–1986
Medical Oncology
- 1981–1984
Internal Medicine
- 1977–1981
Doctor of Medicine
Research
Improved survival with ipilimumab in patients with metastatic melanoma
New England Journal of Medicine · 2010 · 12,191 citations
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
New England Journal of Medicine · 2012 · 10,404 citations
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
New England Journal of Medicine · 2011 · 6,152 citations
83 papers
52 papers
47 papers
46 papers
35 papers
34 papers
30 papers
27 papers
Grants
- 2023–2028
Pathway-Guided Treatment of Immune Checkpoint Inhibitor Therapy-Induced Colon Toxicity
National Cancer Institute · R01
PI · $1.3M · Northwestern University
- 2010–2016
(IND 102,133) Inhibition of Aurora Kinase A as Treatment For Melanoma
Food and Drug Administration · R01
Contact PI · $800K · Vanderbilt University
- 2002–2014
Clinical Investigation in Tumor Immunotherapy
National Cancer Institute · K24
Contact PI · $1.5M · Vanderbilt University
- 2004–2009
National Cancer Institute · P30
Project lead · $2.1M · Vanderbilt University Medical Center
Clinical trials
- 2012–2013
Principal investigator · Terminated · Phase 2
National Cancer Institute (NCI)
- 2011–2015
Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma
Principal investigator · Terminated · Phase 2
Vanderbilt-Ingram Cancer Center
- 2006–2013
The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma
Principal investigator · Completed · Phase 2
Beth Israel Deaconess Medical Center
- 2005–2012
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer
Principal investigator · Completed · Phase 1, Phase 2
National Cancer Institute (NCI)